Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India Brucellosis Market

ID: MRFR/LS/51835-HCR
200 Pages
Rahul Gotadki
December 2024

India Brucellosis Market Research Report: Size, Share, Trend Analysis By Species (Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis, others), By End-User (hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, others), By Diagnosis (serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography, others), By Treatment (antibiotics, vaccines, others), By Region – Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India Brucellosis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

India Brucellosis Market Summary

As per analysis, the India brucellosis market is projected to grow from USD 32.88 Million in 2024 to USD 64.25 Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.28% during the forecast period (2025 - 2035).

Key Market Trends & Highlights

The India brucellosis market is poised for growth driven by increasing awareness and advancements in veterinary healthcare.

  • The veterinary segment remains the largest contributor to the brucellosis market, reflecting a strong focus on livestock health.
  • The human health segment is currently the fastest-growing area, indicating rising public health concerns regarding zoonotic diseases.
  • Diagnostic laboratories are experiencing rapid growth, driven by advancements in diagnostic technologies and increased testing needs.
  • Key market drivers include the rising livestock population and government regulations aimed at controlling brucellosis outbreaks.

Market Size & Forecast

2024 Market Size 32.88 (USD Million)
2035 Market Size 64.25 (USD Million)
CAGR (2025 - 2035) 6.28%

Major Players

Indian Immunologicals Limited (IN), Bharat Biotech International Limited (IN), Hester Biosciences Limited (IN), Zoetis India Limited (IN), Merck Animal Health (US), Vetoquinol India Animal Health Private Limited (IN), Biovet Pvt Ltd (IN), Neogen Corporation (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

India Brucellosis Market Trends

The India Brucellosis Market is currently experiencing a notable evolution, driven by a combination of factors including increased awareness of zoonotic diseases and the rising incidence of brucellosis among livestock. The disease, primarily affecting cattle, goats, and sheep, poses significant health risks to both animals and humans. As a result, there is a growing emphasis on vaccination programs and improved diagnostic methods to control the spread of this infection. Furthermore, the government has been actively promoting initiatives aimed at enhancing livestock health, which may contribute to a more robust market environment. In addition, the demand for effective treatment options and preventive measures is likely to shape the future landscape of the India Brucellosis Market. Stakeholders, including veterinarians and agricultural organizations, are increasingly collaborating to develop comprehensive strategies for disease management. This collaborative approach may lead to advancements in research and development, ultimately benefiting both animal and public health. As awareness continues to grow, the market appears poised for further expansion, with potential opportunities for innovation in diagnostics and therapeutics.

Rising Awareness of Zoonotic Diseases

There is an increasing recognition of the risks posed by zoonotic diseases, including brucellosis, among the Indian population. This heightened awareness is likely to drive demand for preventive measures and effective treatment options, thereby influencing the india brucellosis market.

Government Initiatives for Livestock Health

The Indian government is actively implementing programs aimed at improving livestock health and controlling infectious diseases. These initiatives may enhance the overall management of brucellosis, potentially leading to a more favorable environment for the india brucellosis market.

Advancements in Diagnostic Technologies

Innovations in diagnostic technologies are emerging as a critical factor in the india brucellosis market. Enhanced testing methods could facilitate early detection and better management of the disease, contributing to improved outcomes for both livestock and human health.

India Brucellosis Market Drivers

Growing Public Health Concerns

Growing public health concerns regarding zoonotic diseases are driving attention towards the india brucellosis market. Brucellosis, being a zoonotic disease, poses a risk to human health, particularly among individuals who work closely with livestock. The increasing awareness of the potential transmission of brucellosis from animals to humans has led to heightened scrutiny of livestock health management practices. Public health campaigns aimed at educating farmers and the general population about the risks associated with brucellosis are likely to influence market dynamics. As a result, there is a growing demand for effective prevention and control measures, including vaccines and diagnostic tools, which will further propel the growth of the india brucellosis market.

Increasing Livestock Population

The growth of the livestock population in India is a crucial driver for the india brucellosis market. As of 2023, the livestock population in India was estimated to be over 500 million, with cattle and buffaloes constituting a significant portion. This increase in livestock numbers correlates with a higher incidence of brucellosis, a zoonotic disease that affects both animals and humans. The rising demand for dairy and meat products further exacerbates the situation, as it leads to intensified farming practices. Consequently, the need for effective brucellosis management and control measures becomes paramount. The india brucellosis market is likely to see growth as farmers and veterinarians seek better diagnostic tools and vaccines to mitigate the impact of this disease on livestock health and productivity.

Government Regulations and Policies

Government regulations and policies play a pivotal role in shaping the india brucellosis market. The Indian government has implemented various initiatives aimed at controlling zoonotic diseases, including brucellosis. The National Animal Disease Control Programme (NADCP) launched in 2020 aims to vaccinate livestock against brucellosis, thereby reducing its prevalence. Such policies not only enhance animal health but also protect public health by minimizing the transmission of the disease to humans. The government's commitment to improving livestock health through stringent regulations is expected to drive the demand for brucellosis diagnostics and vaccines. As these initiatives gain traction, the india brucellosis market is poised for growth, with increased investments in research and development to create effective solutions.

Advancements in Veterinary Healthcare

Advancements in veterinary healthcare are transforming the landscape of the india brucellosis market. Innovations in diagnostic technologies, such as rapid testing kits and molecular diagnostics, are enhancing the ability to detect brucellosis in livestock. These advancements not only facilitate early detection but also improve the management of the disease, thereby reducing its spread. Additionally, the development of new vaccines and treatment protocols is expected to bolster the efforts of veterinarians in controlling brucellosis outbreaks. As the veterinary healthcare sector continues to evolve, the india brucellosis market is likely to benefit from increased adoption of these advanced technologies, leading to improved animal health and productivity.

Rising Incidence of Brucellosis Cases

The rising incidence of brucellosis cases in India is a significant driver for the india brucellosis market. Reports indicate that brucellosis remains endemic in several regions, particularly in states with high livestock density. The disease poses a serious threat to both animal and human health, leading to economic losses in the livestock sector. As awareness of the disease's impact grows, there is an increasing demand for effective diagnostic tools and vaccines. The market for brucellosis-related products is likely to expand as healthcare providers and veterinarians seek to address the challenges posed by this disease. Furthermore, the rising number of reported cases may prompt government and private sector investments in research and development, further stimulating the india brucellosis market.

Market Segment Insights

By Species: Brucella abortus (Largest) vs. Brucella melitensis (Fastest-Growing)

In the India brucellosis market, the distribution of market share among different species is notably uneven. Brucella abortus holds the largest share due to its prevalence in cattle and significant impact on livestock health, while Brucella melitensis follows closely as a persistent concern in goat and sheep populations. Other species like Brucella suis and Brucella canis have smaller shares, indicating their limited yet important presence in the overall landscape. Growth trends in this segment point towards Brucella melitensis emerging as the fastest-growing species in the market, driven by increasing awareness of zoonotic diseases and their implications for public health. The rising incidences of brucellosis infections in humans linked to goat herding practices bolster this growth. Additionally, initiatives to improve animal health through vaccination against the dominant species, Brucella abortus, are expected to influence the market dynamics positively.

Brucella abortus (Dominant) vs. Brucella melitensis (Emerging)

Brucella abortus is recognized as the dominant species in the India brucellosis market due to its significant association with cattle, which are vital to agricultural economies. This species poses serious health risks to both livestock and humans, leading to substantial economic losses in farming. In contrast, Brucella melitensis, primarily affecting sheep and goats, is emerging rapidly as a pressing concern, particularly with the increase in small-scale goat farming. Awareness of its zoonotic potential has heightened amid public health discussions, making it a crucial focus for disease management initiatives. As strategies for controlling livestock diseases are implemented, both species are likely to influence the market profoundly.

By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing)

In the India brucellosis market, serological tests dominate the diagnosis segment, capturing a significant share due to their widespread accessibility and cost-effectiveness. These tests are the first line of diagnosis, widely adopted in both rural and urban healthcare settings. Molecular techniques, meanwhile, are gaining traction and represent the fastest-growing segment as they offer higher specificity and the ability to detect the infection at earlier stages. Several factors are driving growth in the diagnosis segment. The increasing prevalence of brucellosis in livestock and rising awareness about zoonotic diseases contribute significantly to this segment's expansion. Additionally, advances in technology and testing methods, such as the introduction of rapid point-of-care tests and improved molecular diagnostics, are enhancing detection rates and encouraging faster diagnosis, thus propelling the market forward.

Serological Tests (Dominant) vs. Molecular Techniques (Emerging)

Serological tests serve as the dominant value in the diagnosis segment of the India brucellosis market. They are favored for their ease of use, speed, and lower costs, making them the primary choice for initial screening. In contrast, molecular techniques, while currently emerging, provide advanced capabilities such as high sensitivity and specificity, allowing for earlier detection of brucellosis. These techniques are increasingly being adopted in specialized laboratories and research institutions, reflecting a shift towards more precise diagnostic methods. This duality highlights an intriguing landscape where traditional approaches meet modern innovation, catering to diverse healthcare requirements.

By Treatment: Vaccines (Largest) vs. Antibiotics (Fastest-Growing)

The market for treatments in the India brucellosis market is diverse, with vaccines holding the largest share. The widespread implementation of vaccination programs among livestock has contributed to the dominance of this segment. Antibiotics, while currently a smaller segment compared to vaccines, are rapidly gaining traction due to increasing awareness of brucellosis management and the need for effective treatment protocols. The 'others' segment, which includes diagnostics and supportive therapies, remains a significant but niche category. Growth trends indicate a strong future for both vaccines and antibiotics, driven by regulatory support and farmers' increasing adoption of preventive measures. The rising incidence of brucellosis in livestock, coupled with a growing focus on animal health, is propelling the demand for both vaccines and antibiotics. Innovations in vaccine formulations are expected to enhance effectiveness and compliance, while developments in antibiotic therapies are crucial for addressing resistant strains of the bacteria.

Vaccines (Dominant) vs. Antibiotics (Emerging)

Vaccines are the dominant force in the treatment segment of the India brucellosis market, providing robust immunity against bacteria transmission to both livestock and humans. Their established use in various vaccination programs makes them a preferred choice among farmers and veterinarians. In contrast, antibiotics, labeled as emerging, play a critical role in the treatment of existing infections. With the rise of antibiotic resistance, the focus on developing new formulations is paramount. Despite their emerging status, the demand for antibiotics is surging as they complement vaccination efforts, highlighting their essential role in managing brucellosis effectively. Innovations and increased accessibility of these treatments are key to addressing this public health challenge.

By End-User: Hospitals & Diagnostic Centers (Largest) vs. Pharmaceutical & Biotechnology Companies (Fastest-Growing)

In the India brucellosis market, the end-user landscape is primarily dominated by hospitals and diagnostic centers, which hold a significant market share due to their critical role in disease diagnosis and management. These facilities utilize advanced diagnostic tools and techniques to identify brucellosis, serving as the primary interface for patient testing and treatment. Meanwhile, academic institutes and pharmaceutical companies also contribute notably, with academic institutions focusing on research and innovation in treatment and diagnosis, while biotech firms are pivotal in developing new vaccines and therapeutics. Growth trends in this segment are heavily influenced by the increasing prevalence of brucellosis, rising awareness regarding zoonotic diseases, and the expanding healthcare infrastructure. Hospitals and diagnostic centers are expected to sustain their dominance as they ramp up testing capabilities. Conversely, pharmaceutical and biotechnology companies are witnessing rapid growth due to heightened investments in research and development, fostering innovation in brucellosis treatments and driving the need for effective diagnostic solutions.

Hospitals & Diagnostic Centers (Dominant) vs. Pharmaceutical & Biotechnology Companies (Emerging)

Hospitals and diagnostic centers play a dominant role in the India brucellosis market as they cater to a broad patient demographic and offer comprehensive diagnostic services. Their established presence and the availability of cutting-edge diagnostic tools enable them to efficiently manage cases of brucellosis. In contrast, pharmaceutical and biotechnology companies are emerging players within this segment, driven by the demand for advanced treatment options and vaccines. These companies leverage their expertise to innovate and adapt to changing market needs, collaborating with healthcare facilities to deliver effective solutions. Their focus on research and development is critical, propelling their growth and positioning them as vital contributors to the overall brucellosis control strategy.

By Test Type: Serological Tests (Largest) vs. Molecular Tests (Fastest-Growing)

In the India brucellosis market, serological tests hold the largest market share due to their widespread application in diagnosing brucellosis efficiently. These tests are favored for their affordability and the extensive availability of testing kits across various regions. Molecular tests, while currently having a smaller share, are rapidly gaining traction due to their accuracy and quicker turnaround times, appealing to healthcare providers seeking reliable diagnostic methods. The growth trends reveal a shift towards molecular testing methods, driven by advancements in technology and increasing awareness about the disease. Factors such as the rising incidence of brucellosis in livestock and human populations in India are propelling the demand for more sophisticated diagnostic tools, making molecular tests the fastest-growing segment in this market.

Serological Tests (Dominant) vs. Culture Tests (Emerging)

Serological tests dominate the India brucellosis testing market due to their established protocols and cost-effectiveness, making them accessible to a larger segment of the population. They are typically the first line of diagnosis in many veterinary and clinical settings. In contrast, culture tests are classified as an emerging segment; while they are critical for identifying live microorganisms and confirming infections, they require more time and specialized laboratory conditions, which limits their widespread use. Despite these challenges, culture tests are beneficial for their accuracy and are likely to see increased adoption as the healthcare infrastructure improves. This interplay between dominant and emerging test types highlights the evolving landscape of brucellosis diagnostics in India.

Get more detailed insights about India Brucellosis Market
Request Free Sample

Key Players and Competitive Insights

The brucellosis market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Indian Immunologicals Limited (IN), Bharat Biotech International Limited (IN), and Zoetis India Limited (IN) are actively engaged in enhancing their product offerings and market reach. Indian Immunologicals Limited (IN) appears to focus on developing advanced vaccines, which may bolster its position in the market. Bharat Biotech International Limited (IN) seems to be leveraging its expertise in biotechnology to introduce novel solutions, while Zoetis India Limited (IN) is likely concentrating on expanding its distribution networks to enhance accessibility to its products. Collectively, these strategies indicate a competitive environment that is not only fragmented but also dynamic, with companies striving to differentiate themselves through innovation and operational efficiency.

In terms of business tactics, localizing manufacturing and optimizing supply chains are becoming increasingly vital. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation may lead to heightened competition, as companies seek to establish a foothold in various regions of India. The collective influence of these key players is likely to drive advancements in product development and distribution strategies, ultimately benefiting the end-users.

In December 2025, Indian Immunologicals Limited (IN) announced the launch of a new brucellosis vaccine aimed at livestock, which is expected to enhance disease control measures in rural areas. This strategic move underscores the company's commitment to addressing public health concerns and improving livestock productivity. The introduction of this vaccine may not only strengthen its market position but also contribute to the overall reduction of brucellosis incidence in India.

In November 2025, Bharat Biotech International Limited (IN) entered into a collaboration with a leading agricultural university to conduct research on brucellosis prevention strategies. This partnership is likely to facilitate the development of innovative solutions tailored to local needs, thereby enhancing the company's research capabilities and market relevance. Such collaborations may also foster knowledge exchange and drive advancements in vaccine technology.

In October 2025, Zoetis India Limited (IN) expanded its distribution network by partnering with local veterinary clinics across several states. This strategic expansion is expected to improve product accessibility and customer engagement, potentially leading to increased sales and market penetration. By enhancing its distribution capabilities, Zoetis India Limited (IN) may position itself as a leader in the brucellosis market, catering to the growing demand for effective veterinary solutions.

As of January 2026, current trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancements and supply chain reliability is becoming evident. Companies that prioritize innovation and sustainability are likely to gain a competitive edge, as the market evolves towards more sophisticated solutions that address both economic and health-related challenges.

Key Companies in the India Brucellosis Market include

Industry Developments

The India Brucellosis Market is witnessing significant developments, with increasing awareness of animal health and the economic impact of brucellosis. Allied Veterinary Products, Hester Biosciences, and Zoetis are among the companies enhancing their research initiatives and product offerings to tackle this zoonotic disease.

In recent months, there has been a notable rise in public health campaigns initiated by the Indian government aimed at educating farmers about brucellosis and its control measures. Recent market valuations have shown a positive trend, largely due to the heightened investment in diagnostics and vaccines, particularly from companies like Biocon and Merck Animal Health, contributing to overall market growth.

Additionally, in March 2023, substantial investments were made in the production of improved diagnostic tests for brucellosis, highlighting the focus on innovative solutions. Mergers and acquisitions remain relatively stable in this sector, with an emphasis on collaboration for Research and Development in vaccine technologies.

The collective efforts of firms like Virbac, IDEXX Laboratories, and Boehringer Ingelheim are pivotal in addressing this public health challenge, enhancing the market's capacity to respond effectively to brucellosis outbreaks across India.

Future Outlook

India Brucellosis Market Future Outlook

The India brucellosis market is projected to grow at a 6.28% CAGR from 2025 to 2035, driven by increased livestock health awareness and advancements in diagnostic technologies.

New opportunities lie in:

  • Development of mobile diagnostic units for rural areas
  • Investment in vaccine production facilities to enhance supply
  • Partnerships with agricultural cooperatives for awareness campaigns

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in livestock disease management.

Market Segmentation

India Brucellosis Market End Use Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Pharmaceutical Companies

India Brucellosis Market Test Type Outlook

  • Serological Tests
  • Molecular Tests
  • Culture Tests
  • Field Tests

India Brucellosis Market Application Outlook

  • Veterinary
  • Human Health
  • Research
  • Diagnostics

India Brucellosis Market Pathogen Type Outlook

  • Brucella abortus
  • Brucella melitensis
  • Brucella suis
  • Brucella canis

India Brucellosis Market Distribution Channel Outlook

  • Direct Sales
  • Online Sales
  • Distributors
  • Retail

Report Scope

MARKET SIZE 2024 32.88(USD Million)
MARKET SIZE 2025 35.53(USD Million)
MARKET SIZE 2035 64.25(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.28% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Indian Immunologicals Limited (IN), Bharat Biotech International Limited (IN), Hester Biosciences Limited (IN), Zoetis India Limited (IN), Merck Animal Health (US), Vetoquinol India Animal Health Private Limited (IN), Biovet Pvt Ltd (IN), Neogen Corporation (US)
Segments Covered Application, End Use, Pathogen Type, Distribution Channel, Test Type
Key Market Opportunities Increasing demand for effective diagnostic tools and vaccines in the india brucellosis market presents significant growth opportunities.
Key Market Dynamics Rising awareness of brucellosis prevention drives demand for vaccines and diagnostic tools in India's livestock sector.
Countries Covered India
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch
Leave a Comment

FAQs

What is the current valuation of the India brucellosis market in 2024?

<p>The overall market valuation was $49.32 Million in 2024.</p>

What is the projected market valuation for the India brucellosis market by 2035?

<p>The projected valuation for 2035 is $103.5 Million.</p>

What is the expected CAGR for the India brucellosis market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during this period is 6.97%.</p>

Which companies are the key players in the India brucellosis market?

<p>Key players include Zoetis, Merck & Co., Boehringer Ingelheim, Ceva Santé Animale, Heska Corporation, Virbac, Vetoquinol, and Phibro Animal Health Corporation.</p>

What are the main species segments in the India brucellosis market and their valuations?

<p>The species segments include Brucella abortus ($15.0 - $30.0 Million), Brucella melitensis ($10.0 - $20.0 Million), and others.</p>

What diagnostic methods are utilized in the India brucellosis market?

<p>Diagnostic methods include serological tests ($5.0 - $10.0 Million) and molecular techniques ($8.0 - $15.0 Million), among others.</p>

What treatment options are available in the India brucellosis market?

<p>Treatment options include antibiotics ($20.0 - $42.0 Million) and vaccines ($15.0 - $30.0 Million).</p>

Who are the primary end-users in the India brucellosis market?

<p>Primary end-users include hospitals & diagnostic centers ($20.0 - $42.0 Million) and pharmaceutical & biotechnology companies ($15.0 - $30.0 Million).</p>

How does the market for Brucella canis compare to other species in terms of valuation?

<p>The market for Brucella canis is valued between $7.0 - $15.0 Million, which is lower than Brucella abortus and Brucella melitensis.</p>

What trends are anticipated in the India brucellosis market as it approaches 2035?

<p>Trends may indicate growth driven by advancements in diagnostics and treatment, alongside increasing awareness of brucellosis.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓